Inflammasome mediated in situ cancer vaccine activated by schottky heterojunction for augmented immunotherapy
Journal of Controlled Release · 2025-04 · 380 · 1184-1197
DOI: 10.1016/j.jconrel.2025.02.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-04. Verfasst von Chengzhilin Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Science and Technology Innovation Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medica…. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines, Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
In situ cancer vaccines have emerged as an attractive paradigm for cancer immunotherapy. Nevertheless, insufficient antigens production, weak antigen presentation and immunosuppressive tumor microenvironment impeded the effectiveness of tumor immunotherapy. Herein, we constructed the NLRP3 inflammasome mediated in situ cancer vaccine (FPLB), in which rod shaped α-Fe2O3@Pt schottky heterojunction loaded with lactate oxidase (LOx) and surface-modified with bovine serum albumin and folic acid conjugation (FA-BSA). On the one hand, FPLB NPs utilizes its physicochemical properties of high aspect ratio to induce the breakdown of dendritic cells (DCs) lysosomes and the release of cathepsin B, thereby activating the NLRP3 inflammasome. Besides, the formation of "circulating pump" by harnessing catalase (CAT) activity and LOx activity could continuously consume lactic acid to alleviate the inactivation of cytokines induced by lactic acid excess, thereby transforming inflammatory activators into controllable nanoadjuvants. On the other hand, the "circulating pump" not only catalyze continuous generation of pyruvic acid to block the cell cycle, but also boosts charge utilization efficiency for excellent sonodynamic therapy (SDT) effect under ultrasound irradiation, thereby inducing the apoptosis or necrosis of tumor cells and releasing tumor-associated antigens (TAAs). FPLB demonstrates a significant NLRP3-mediated anti-tumor immune response both in vitro and in vivo. This strategy provides a new paradigm for the construction of NLRP3 inflammasome-mediated in situ cancer vaccines, which will have profound implications for the application of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Science and Technology Innovation Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250021, S…
- The Institute of Physical Organic Chemistry of the National Academy of Sciences of Belarus, Minsk 220072, Belarus.
- School of Biomedical Engineering & The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
- Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China. Electronic address: zhaomqsd@163.com.
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: jwjiao@ioz.ac.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Li, C., Zhang, N., Xu, Z., Rong, Z., Song, C., Zhang, Y., Hua, Y., Hu, H., He, Q., Shmanaid, V. V., Xia, M., Zhang, H., Zhao, M., Jiao, J., & Zheng, R. (2025). Inflammasome mediated in situ cancer vaccine activated by schottky heterojunction for augmented immunotherapy. Journal of Controlled Release, 380, 1184-1197. https://doi.org/10.1016/j.jconrel.2025.02.059
Vancouver
Li C, Zhang N, Xu Z, Rong Z, Song C, Zhang Y, et al. Inflammasome mediated in situ cancer vaccine activated by schottky heterojunction for augmented immunotherapy. Journal of Controlled Release. 2025;380:1184-1197. doi:10.1016/j.jconrel.2025.02.059
BibTeX
@article{Li2025,
author = {Li, Chengzhilin and Zhang, Nianlei and Xu, Ziang and Rong, Zhonghou and Song, Cong and Zhang, Yachao and Hua, Yue and Hu, Houyang and He, Qingbin and Shmanaid, Vadim V and Xia, Ming and Zhang, Haiyuan and Zhao, Miaoqing and Jiao, Jianwei and Zheng, Runxiao},
title = {Inflammasome mediated in situ cancer vaccine activated by schottky heterojunction for augmented immunotherapy},
journal = {Journal of Controlled Release},
year = {2025},
volume = {380},
pages = {1184--1197},
doi = {10.1016/j.jconrel.2025.02.059}
}
EUVIMED